Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAFV600E-mutated erdheim-chester disease

Journal of Clinical Oncology

Volumn 33, Issue 5, 2015, Pages 411-418

  Haroche, Julien ^a,b   Cohen Aubart, Fleur ^a,b   Emile, Jean François ^d   Maksud, Philippe ^a   Drier, Aurélie ^a   Tolédano, Dan ^a   Barete, Stéphane ^a,b   Charlotte, Frédéric ^a,b   Cluzel, Philippe ^a,b   Donadieu, Jean ^c   Benameur, Neïla ^a   Grenier, Philippe A ^a,b   Besnard, Sophie ^e   Ory, Jean Paul ^f   Lifermann, François ^g   Idbaih, Ahmed ^a,b   Granel, Brigitte ^h   Graffin, Bruno ^a,i   Hervier, Baptiste ^a,b   Arnaud, Laurent ^a,b   Amoura, Zahir ^b,c   more..

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c ARMAND TROUSSEAU HOSPITAL   (France)

^d LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^e PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^f Centre Hospitalier Régional de Vesoul   (France)

^g Centre Hospitalier de Dax Côte d'Argent   (France)

^h HÔPITAL NORD   (France)

ⁱ Hôpital d'Instruction des Armées Legouest   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INFLIXIMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STEROID; VEMURAFENIB; B RAF KINASE; BRAF PROTEIN, HUMAN; FLUORODEOXYGLUCOSE F 18; GLUTAMIC ACID; INDOLE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; SULFONAMIDE; VALINE;

ADULT; AGED; ARTHRALGIA; ARTICLE; BASAL CELL CARCINOMA; BRAF GENE; BRAIN; CARDIOVASCULAR SYSTEM; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DARIER DISEASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG UPTAKE; ERDHEIM CHESTER DISEASE; ESOPHAGUS; FEMALE; FEMUR; FOLLOW UP; GENE; GENE MUTATION; HAIR LOSS; HUMAN; HUMERUS; LANGERHANS CELL HISTIOCYTOSIS; MALE; MANDIBLE; MAXILLARY SINUS; MEDIASTINUM; MOLECULARLY TARGETED THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTOSENSITIVITY; PLEURA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QT PROLONGATION; SKULL BASE; SQUAMOUS CELL CARCINOMA; STEROID THERAPY; SUBCUTANEOUS TISSUE; TIBIA; TREATMENT DURATION; TREATMENT RESPONSE; XEROSIS; CLINICAL TRIAL; DIAGNOSTIC USE; DRUG EFFECTS; ERDHEIM-CHESTER DISEASE; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; PROCEDURES; SCINTISCANNING; SKIN; TREATMENT OUTCOME;

ADULT; AGED; ERDHEIM-CHESTER DISEASE; FEMALE; FLUORODEOXYGLUCOSE F18; GLUTAMIC ACID; HUMANS; INDOLES; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; POSITRON-EMISSION TOMOGRAPHY; PROTO-ONCOGENE PROTEINS B-RAF; RADIOPHARMACEUTICALS; SKIN; SULFONAMIDES; TREATMENT OUTCOME; VALINE;

EID: 84922354803     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.1950     Document Type: Article

References (34)

1. Chester W: Uber lipoid granulomatose. Virchows Arch 279:561-602, 1930
2. Haroche J, Arnaud L, Cohen-Aubart F, et al: Erdheim-Chester disease. Rheum Dis Clin North Am 39:299-311, 2013
3. Braiteh F, Boxrud C, Esmaeli B, et al: Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferonalpha. Blood 106:2992-2994, 2005
4. Haroche J, Amoura Z, Trad SG, et al: Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement Results in eight patients. Arthritis Rheum 54:3330-3336, 2006
5. Arnaud L, Hervier B, Néel A, et al: CNS nvolvement and treatment with interferon-α are ndependent prognostic factors in Erdheim-Chester disease: A multicenter survival analysis of 53 patients. Blood 117:2778-2782, 2011
6. Haroche J, Amoura Z, Dion E, et al: Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: Report of 6 new cases and a literature review. Medicine (Baltimore) 83:371-392, 2004
7. Aouba A, Georgin-Lavialle S, Pagnoux C, et al: Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood 116:4070-4076, 2010
8. Myra C, Sloper L, Tighe PJ, et al: Treatment of Erdheim-Chester disease with cladribine: A rational approach. Br J Ophthalmol 88:844-847, 2004
9. Haroche J, Amoura Z, Charlotte F, et al: Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis. Blood 111:5413-5415, 2008
10. Janku F, Amin HM, Yang D, et al: Response of histiocytoses to imatinib mesylate: Fire to ashes. J Clin Oncol 28:e633-e636, 2010
11. Dagna L, Corti A, Langheim S, et al: Tumor necrosis factor a as a master regulator of inflammation in Erdheim-Chester disease: Rationale for the treatment of patients with infliximab. J Clin Oncol 30: e286-e290, 2012
12. Badalian-Very G, Vergilio JA, Degar BA, et al: Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 116:1919-1923, 2010
13. Haroche J, Charlotte F, Arnaud L, et al: High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 120:2700-2703, 2012
14. Emile JF, Charlotte F, Amoura Z, et al: BRAF mutations in Erdheim-Chester disease. J Clin Oncol 31:398, 2013
15. Cangi MG, Biavasco R, Cavalli G, et al: BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. Ann Rheum Dis [epub ahead of print on March 26, 2014]
16. Haroche J, Cohen-Aubart F, Emile JF, et al: Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 121:1495-1500, 2013
17. Arnaud L, Malek Z, Archambaud F, et al: 18F-fluorodeoxyglucose-positron emission tomography scanning is more useful in followup than in the initial assessment of patients with Erdheim-Chester disease. Arthritis Rheum 60:3128-3138, 2009
18. Adams MC, Turkington TG, Wilson JM, et al: A systemic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol 195: 310-320, 2010
19. Avril NE, Weber WA: Monitoring response to treatment in patients utilizing PET. Radiol Clin N Am 43:189-204, 2005
20. Jacene HA, Leboulleux S, Baba S, et al: Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy. J Nucl Med 50:1760-1769, 2009
21. Vanderhoek M, Perlman SB, Jeraj R, et al: Impact of the definition of peak standardized uptake value on quantification of treatment response. J Nucl Med 53:4-11, 2012
22. Jerusalem G, Beguin Y, Fassotte MF, et al: Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical conventional tomography scan imaging. Blood 94:429-433, 1999
23. Wahl RL, Jacene H, Kasamon Y, et al: From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med 50:122S-150S, 2009 (suppl 1)
24. Haroche J, Cluzel P, Toledano D, et al: Images in cardiovascular medicine: Cardiac involvement in Erdheim-Chester disease-Magnetic resonance and computed tomographic scan imaging in a monocentric series of 37 patients. Circulation 119:e597-e598, 2009
25. Tirkes T, Hollar MA, Tann M, et al: Response criteria in oncologic imaging: Review of traditional and new criteria. Radiographics 33:1323-1341, 2013
26. Drier A, Haroche J, Savatovsky J, et al: Cerebral, facial, and orbital involvement in Erdheim-Chester disease: CT and MR imaging findings. Radiology 255:586-594, 2010
27. Hervier B, Haroche J, Arnaud L, et al: Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood 124:1119-1126, 2014
28. Diamond EL, Abdel-Wahab O, Pentsova E, et al: Detection of an NRAS mutation in Erdheim-Chester disease. Blood 122:1089-1091, 2013
29. Trotti A, Colevas AD, Setser A, et al: CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176-181, 2003
30. Boussemart L, Routier E, Mateus C, et al: Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: A study of 42 patients. Ann Oncol 24:1691-1697, 2013
31. Ascierto PA, Minor D, Ribas A, et al: Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 31:3205-3211, 2013
32. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516, 2011
33. Killu AM, Liang JJ, Jaffe AS: Erdheim-Chester disease with cardiac involvement successfully treated with anakinra. Int J Cardiol 167:e115-e117, 2013
34. Darstein F, Kirschey S, Heckl S, et al: Successful treatment of Erdheim-Chester disease with combination of interleukin-1-targeting drugs and high-dose glucocorticoids. Intern Med J 44:90-92, 2014